Core Viewpoint - Toxin Pharmaceutical's subsidiary, Jingquan Biotechnology, has successfully obtained Self-GRAS status for its product, Glyceryl Phosphoryl Choline, from the FDA, which is a significant milestone for market entry in the U.S. and other regions recognizing FDA standards [1] Group 1 - Toxin Pharmaceutical's subsidiary, Jingquan Biotechnology, completed a rigorous scientific evaluation for Glyceryl Phosphoryl Choline [1] - The Self-GRAS certification is one of the highest levels of recognition established by the FDA for the safety of food additives and dietary ingredients [1] - The successful certification provides a critical "passport" for the product to enter the U.S. market and other international markets that recognize FDA standards [1]
拓新药业(301089.SZ)：子公司产品通过美国Self-GRAS认证